Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Allegiant Air Unexpectedly Received 3 Additional Boeing 737 MAX 8s Last Year
At the end of Q3 in 2024, Allegiant Air expected to take just a single Boeing 737 MAX 8-200 delivery by the end of the year.